Publications by authors named "Gary D Steinberg"

Claim this Profile
L
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.
Lexiaochuan Wen, Hiroko Miyagi, Philippe E Spiess, Alice Yu, Cathy L Mendelsohn, Gary D Steinberg

Nat Rev Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.
Amanda A Myers, Ruchika Talwar, Zhigang Duan, Patrick Hensley, Yair Lotan, Gary D Steinberg

Eur Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding patient perspectives in the management of their muscle-invasive bladder cancer.
Deepro Chowdhury, Andrea B Apolo, Di Maria Jiang, Eila C Skinner, Stephanie Chisolm, Gary D Steinberg

BJU Int· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta, Gary D Steinberg

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta, Gary D Steinberg

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urachal Carcinoma: Insights From a National Database.
Angelo Orsini, Gabriele Bignante, Francesco Lasorsa, Eugenio Bologna, Spencer M Mossack, Gary D Steinberg

Clin Genitourin Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Gary D Steinberg

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Gary D Steinberg

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Gary D Steinberg

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, Neal D Shore, Gary D Steinberg

J Urol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Gary D Steinberg, Neal D Shore, Joan Palou Redorta, Matthew D Galsky, Jens Bedke

Future Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interruptions in bladder cancer care during the COVID-19 public health emergency.
John L Gore, Kristin Follmer, Jason Reynolds, Michael Nash, Christopher B Anderson, Gary D Steinberg

Urol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.
Seyedeh-Sanam Ladi-Seyedian, Alireza Ghoreifi, Badrinath Konety, Kamal Pohar, Jeffrey M Holzbeierlein, Gary D Steinberg

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant personalized cancer vaccines: the final frontier?
Guilhem Richard, Nicole Ruggiero, Gary D Steinberg, William D Martin, Anne S De Groot

Expert Rev Vaccines· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, Trinity J Bivalacqua, Peter C Black, Gary D Steinberg

J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
Joshua J Meeks, Peter C Black, Matthew Galsky, Petros Grivas, Noah M Hahn, Gary D Steinberg

Eur Urol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
John L Gore, Erika M Wolff, Bryan A Comstock, Kristin M Follmer, Michael G Nash, Gary D Steinberg

BMC Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Elaine Chang, Noah M Hahn, Seth P Lerner, Jaleh Fallah, Sundeep Agrawal, Gary D Steinberg

Bladder Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
Brant A Inman, Noah M Hahn, Kelly Stratton, Ryan Kopp, Alex Sankin, Gary D Steinberg

Eur Urol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?
Muhannad Alsyouf, Seyedeh-Sanam Ladi-Seyedian, Badrinath Konety, Kamal Pohar, Jeffrey M Holzbeierlein, Gary D Steinberg

Urol Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Siamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, Gary D Steinberg, Manju Aron

Urol Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter.
Ashish M Kamat, Niyati Lobo, Seth P Lerner, Roger Li, Justin T Matulay, Gary D Steinberg

Bladder Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
Meera R Chappidi, Heiko Yang, Maxwell V Meng, Trinity J Bivalacqua, Siamak Daneshmand, Gary D Steinberg

J Urol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, Tanner Miest, Stephen A Boorjian, Gary D Steinberg

Eur Urol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
Guilhem Richard, Michael F Princiotta, Dominique Bridon, William D Martin, Gary D Steinberg

Expert Rev Vaccines· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis